This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

mitzy, what makes you think that the company is worth 15 a share??? I bought in March when sp was 71p and as it kept falling was always tempted to buy more especially when just over 50p. Was annoyed that if more positive I could have improved profits in short term but if you have any info that suggests movement over 5 never mind 15 I suppose it doesn't matter if next stock-up is in the 70's again.
I backed this one because any breakthrough with cancer/aids treatments seems like a license to print money.
Whats your info?

andy I bought at 6p to 20p last year and even then believed they had the potential to reach 15 a share..at one stage they were as low as 3p because the MM's didnt really understand the company and I think that remains the same today.It could be the next British Biotech which was valued at some 2000m about 10 years ago on the promise of a anti-cancer drug which never materialised.I am positive its worth at least 20 times more than it is today.

Brewin Dolphin to issue Brokers note next week with a 400p plus target for end 2005 which values MMG at 200m.

Mitzy if you can get your hands on it please post it here.

cheers GF.

Lifted this from someone who had lifted it from the Mike Walters site........

In the interests of clearing up some confusion, I hope that Mike Walters will not mind me posting a couple of quotes from his article on here. He does seem to have access to rather more information than appears in the RNS.

He says: "Genvax is already a fair way down the testing process. It is in clinical trials against three forms of cancer. That puts it ahead of ruthenium, especially since one of the trials is pretty serious stuff, tackling follicular lymphoma, a common form of B-cell lymphoma.

This is effectively a phase IIa trial, testing for efficacy on 25 patients. It began in 2001 and the last patient joined early in 2004. Full evaluation of the results is expected by March 2005. Those entering the trials were in a bad way, and might normally have only five years life expectancy. After three years, all are alive and reasonably well."

Later he says: "It is all done on modest staffing there are ten employees at MMI and tight cash control. The Genvax funding has come from several cancer charities, while MMI is paying legal and patent costs, and will fund development costs.

Quite when ruthenium and others will move into clinical trials is not clear. Best is saying within the next year. When they do, that will add significantly to the notional value of the portfolio. But much depends on how well the company can win recognition for what it is already doing.

At around 80p, it is capitalised at les than 40m. All of the opposition IPO2IPO, BTG, or maybe Oxford Biomedica is much more highly valued up to five times the MMI rating.

cheers Gf

Mitzy,

I hope the note to brokers happens after Tuesday as sod's law I'm away on business and need to raise funds in my portfolio to top up!!
I like this stock and glad that someone else sees the potential.

How did you get the info and when do you expect the note to go out?

andysmith

The revised note is due anytime now with a valuation of up to 200m....DB is doing a round of presentations and this is the figure he is talking of over the next 15 months...

Mitzy post please post it as soon as you get it.


cheers GF.

Note in IC confirms a possible re-rating but does not suggest by how much.
Question is whether to gamble and stock up early next week or wait and see, I suspect the former as we all know this is a gamble but with high rewards is success starts to achieved.

What do you think?

Hi andy, I beleive you are correct but I dont and wont go along with these Broker recos of 400p per share.

I beleive as short term 125p a share unless we get some visibility of earnings, which is very unlikely to say the least. Never the less I still stand by this one and feel it could have a fantastic future.

Cheers GF.

Hopefully we will get the new Brokers report in the next few days.

cheers Gf.

Started to move north again.

cheers Gf

Broker note anyone?.

cheers GF.

Its been delayed for 3 weeks....

Some big news coming out then?.

cheers Gf

Yes thats right but we will have to wait at least 3 weeks..

Thanks Mitzy, please keep us informed here with any info, seen you on the other big site, but please dont forget us.

cheers GF

what affect do you think the recent news will have on the company has a whole ?

RNS Number:8144C
Medical Marketing Int'l Group PLC
10 September 2004

FOR IMMEDIATE RELEASE 10TH SEPTEMBER 2004



MMI ANNOUNCES FURTHER LABHOTEL(R) PARTNER


Medical Marketing International Group plc (MMI) (LSE:MMG) the Cambridge,
UK-based biopharmaceutical development company focussed on cancer, AIDS and
'superbugs' announces that it has reached an exclusive agreement with Corbett
Research, an Australian Biotechnology company at the forefront of the
development of genetic analysis laboratory equipment, to supply its systems to
MMI's LabHotel(R).

LabHotel(R) has a unique business model as it provides fledgling biotechnology
companies based at MMI's Bioscience Innovation Centre (BIC) in Cambridge, UK,
access to sophisticated equipment managed to industrial standards on a
short-term rental basis rather than incurring capital costs. LabHotel(R) already
contains laboratories dedicated to tissue culture, microbiology and protein
purification services with further services in the pipeline.

David Best, Chairman of MMI, explained: "We are delighted that another leader,
Corbett Research is supporting our LabHotel(R). The capital cost of equipment is
often prohibitive resulting in emerging biotech companies being unable to
generate quality data that will satisfy themselves, potential partners and
investors. MMI's LabHotel(R) solves this problem by enabling the manufacturers of
world-class equipment to install their systems in a professionally managed
purpose-built centre. Through this innovative service we believe that we will
increase occupancy as well as fee levels and create greater opportunities for
MMI to take advantage of investing in these exciting businesses as well as
providing essential facilities for our in-house biobabies. Our goal is that
LabHotel(R) becomes the centre of excellence for biotechnology".

John Corbett, Director of Corbett Research commented: "This innovative approach
provides excellent opportunities for start-up companies wanting proof of
principle. The Lab Hotel is the ideal venue for us as an organisation to
showcase our latest equipment and to work with emerging companies to help them
develop new technologies"

A good deal thanks for posting it Mick.

cheers GF.